MARC N. CASPER - 22 Aug 2025 Form 4 Insider Report for THERMO FISHER SCIENTIFIC INC. (TMO)

Role
Chairman & CEO, Director
Signature
/s/ Melodie T. Morin, Attorney-in-Fact for Marc N. Casper
Issuer symbol
TMO
Transactions as of
22 Aug 2025
Net transactions value
-$2,469,686
Form type
4
Filing time
26 Aug 2025, 16:32:22 UTC
Previous filing
21 Aug 2025
Next filing
02 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
CASPER MARC N Chairman & CEO, Director 168 THIRD AVENUE, WALTHAM /s/ Melodie T. Morin, Attorney-in-Fact for Marc N. Casper 26 Aug 2025 0001216055

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMO Common Stock Options Exercise $2,539,900 +10,000 +8.7% $253.99 125,174 22 Aug 2025 Direct
transaction TMO Common Stock Sale $2,913,829 -5,823 -4.7% $500.40 119,351 22 Aug 2025 Direct F1, F2
transaction TMO Common Stock Sale $1,795,405 -3,579 -3% $501.65 115,772 22 Aug 2025 Direct F1, F3
transaction TMO Common Stock Sale $300,351 -598 -0.52% $502.26 115,174 22 Aug 2025 Direct F1, F4
holding TMO Common Stock 11,300 22 Aug 2025 By Alison Casper 2020 Irrevocable Trust F5
holding TMO Common Stock 14,608 22 Aug 2025 By Floral Park Associates, Inc.
holding TMO Common Stock 5,000 22 Aug 2025 By MNC 2020 Irrevocable Trust F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMO Stock Option (Right to Buy) Options Exercise $0 -10,000 -29% $0.000000 24,754 22 Aug 2025 Common Stock 10,000 $253.99 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 28, 2025.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $500.001 to $500.98, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $501.05 to $501.99, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.02 to $502.37, inclusive.
F5 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.
F6 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.
F7 The option vested in four equal installments on February 26, 2020, 2021, 2022, and 2023.